PDF(Pubmed)
Abstract：
OBJECTIVE: To study the effect of recombinant human growth hormone (rhGH) treatment on the growth velocities and serum index expressions of short stature children.
METHODS: 56 short stature children admitted to our hospital from January 2018 to January 2020 were recruited as the study cohort. All the children were treated with rhGH. After six months of treatment, their serum indicators [ghrelin, Nesfatin-1, bone-specific alkaline phosphate (BAP), insulin-like growth factor 1 (IGF-1)], their growth velocity indicators [body mass index (BMI), height, growth velocity (GV)], their blood lipid levels [triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high and low density lipoprotein (HDL)], their insulin statuses [fasting insulin (FINS), their homeostasis model assessment of insulin resistance (HOMA-IR)], and their thyroid function index [thyroid stimulating hormone (TSH), 3\'-triiodothyronine (T3), 4\'-triiodothyronine (T4)] level changes before and after the treatment were compared.
RESULTS: (1) After the treatment, the children\'s serum ghrelin and IGF-1 levels increased in comparison with their pre-treatment levels (P<0.05), and their nesfatin-1 levels decreased (P<0.05). (2) After the treatment, the children\'s BMI, height, and GV increased in comparison with their pre-treatment levels (P<0.05). (3) After the treatment, the children\'s TG levels were noticeably higher than they were before the treatment (P<0.05), and the TC and LDL levels were remarkably lower than they were before the treatment (P<0.05). (4) After the treatment, the children\'s T3 and T4 levels were significantly higher compared to their levels before the treatment (P<0.05).
CONCLUSIONS: GH can promote the development and growth of short stature children, improve their related serum indicator levels, and does not induce metabolic dysfunction.
METHODS: 56 short stature children admitted to our hospital from January 2018 to January 2020 were recruited as the study cohort. All the children were treated with rhGH. After six months of treatment, their serum indicators [ghrelin, Nesfatin-1, bone-specific alkaline phosphate (BAP), insulin-like growth factor 1 (IGF-1)], their growth velocity indicators [body mass index (BMI), height, growth velocity (GV)], their blood lipid levels [triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high and low density lipoprotein (HDL)], their insulin statuses [fasting insulin (FINS), their homeostasis model assessment of insulin resistance (HOMA-IR)], and their thyroid function index [thyroid stimulating hormone (TSH), 3\'-triiodothyronine (T3), 4\'-triiodothyronine (T4)] level changes before and after the treatment were compared.
RESULTS: (1) After the treatment, the children\'s serum ghrelin and IGF-1 levels increased in comparison with their pre-treatment levels (P<0.05), and their nesfatin-1 levels decreased (P<0.05). (2) After the treatment, the children\'s BMI, height, and GV increased in comparison with their pre-treatment levels (P<0.05). (3) After the treatment, the children\'s TG levels were noticeably higher than they were before the treatment (P<0.05), and the TC and LDL levels were remarkably lower than they were before the treatment (P<0.05). (4) After the treatment, the children\'s T3 and T4 levels were significantly higher compared to their levels before the treatment (P<0.05).
CONCLUSIONS: GH can promote the development and growth of short stature children, improve their related serum indicator levels, and does not induce metabolic dysfunction.
摘要：
暂无翻译
